secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2024-10-08T23:59:59+00:00
Accession:  0001628280-24-042478
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo doses first patient in Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa
--------------------------------------------------------------------------------

- Phase 2 LOTUS trial enrolling ~180 adults with moderate to severe hidradenitis suppurativa.
- Two dose regimens of AVTX-009 vs placebo in 1:1:1 randomization over 16-week treatment phase.
- Primary endpoint: proportion achieving HiSCR75 at Week 16; topline data expected in 2026.
- CEO Garry Neil cited high potency potential for best-in-class treatment option.
- AVTX-009 is a humanized monoclonal antibody targeting IL-1β with high affinity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024042478/0001628280-24-042478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024042478/avtx-20241008.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-042478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer